Cyclopharm (ASX:CYC) has secured an intellectual property milestone, with the United States Patent and Trademark Office granting the maximum allowable five-year patent extension for its TECHNEGAS Kit, extending market exclusivity in the US to 2031.
The extension follows a comprehensive review by both the USPTO and the US Food and Drug Administration, which confirmed TECHNEGAS' eligibility under 35 U.S.C. ยง 156.
Originally set to expire in 2026, the patent's new expiry date provides Cyclopharm with a strengthened foothold in the US.
The extension ensures uninterrupted exclusivity for TECHNEGAS, a nuclear medicine agent used for functional lung ventilation imaging in diagnosing pulmonary embolism and emerging indications beyond PE.
It removes the threat of near-term generic competition, enabling Cyclopharm to fully capitalize on its US commercial rollout.
Cyclopharm Managing Director James McBrayer called the extension "a significant achievement," reflecting years of strategic effort aligned with US FDA regulatory approval processes.
He emphasised the development as a validation of the company's long-term vision and a boost to its ongoing US commercialisation.
Cyclopharm is also advancing initiatives to protect the TECHNEGAS platform beyond 2031.
These include next-generation technologies, new patent filings, and complementary IP strategies aimed at maintaining leadership in pulmonary imaging.